Eight patients treated in Parts A and B of THIO-101 have crossed the two-year overall survival mark — a benchmark that carries real weight in third-line advanced NSCLC, where durable responses to any regimen are uncommon. That survival signal is now the engine behind MAIA Biotechnology’s latest regulatory move: FDA clearance of an amended IND that opens U.S. enrollment for the Phase 2 THIO-101 expansion, specifically targeting patients who have progressed through both a checkpoint inhibitor and chemotherapy.
The cleared IND amendment does more than unlock domestic sites. It incorporates updated manufacturing protocols — new contract manufacturers, revised formulation, and improved storage conditions for ateganosine — changes that matter when regulatory reviewers evaluate whether a Phase 2 dataset can anchor an Accelerated Approval filing. MAIA is explicit that expansion data from Parts C and D, which are restricted to third-line patients only, are intended to strengthen exactly that filing pathway. The company already holds FDA Fast Track designation for ateganosine in NSCLC, granted in July 2025, which enables rolling review and makes the drug eligible for Accelerated Approval consideration — a meaningful structural advantage as enrollment scales.
The trial’s design is worth examining closely. THIO-101 sequences low-dose ateganosine before cemiplimab, a PD-(L)1 inhibitor with existing FDA approvals in NSCLC, testing the hypothesis that telomere-targeted DNA damage primes innate and adaptive immune responses that a checkpoint inhibitor can then amplify. The mechanism is distinct: ateganosine is incorporated into telomeres by telomerase, generating damaged telomeric fragments that activate the cGAS/STING pathway and T-cell responses. The expansion cohort’s primary endpoint is overall response rate, a surrogate capable of supporting Accelerated Approval if the signal is sufficiently compelling. One U.S. site — Summit Medical Group in New Jersey — is already active, with a second expected within weeks and up to five planned for 2026.
Running in parallel is the pivotal Phase 3 THIO-104 trial, a 1:1 randomized study of up to 300 third-line NSCLC patients comparing ateganosine plus checkpoint inhibitor against investigator’s choice chemotherapy, with overall survival as the endpoint. The number to track is the ORR emerging from Parts C and D: if it mirrors or exceeds the early survival durability seen in Parts A and B, MAIA will have a credible basis to file for Accelerated Approval well ahead of THIO-104 reading out.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
